Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

被引：0

作者：

Kow, Chia Siang ^{[1
]}

Ramachandram, Dinesh Sangarran ^{[2
]}

Hasan, Syed Shahzad ^{[3
]}

Thiruchelvam, Kaeshaelya ^{[1
,4
]}

机构：

[1] Int Med Univ, Sch Pharm, Kuala Lumpur, Malaysia

[2] Monash Univ Malaysia, Sch Pharm, Bandar Sunway, Selangor, Malaysia

[3] Univ Huddersfield, Sch Appl Sci, Huddersfield, England

[4] Int Med Univ, 126 Jalan Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia

来源：

INTERNATIONAL JOURNAL OF PHARMACY PRACTICE | 2024年 / 32卷 / 03期

关键词：

uricosuric; mortality; COVID-19; URIC-ACID;

D O I：

10.1093/ijpp/riae003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objectives To determine risks associated with uricosurics in COVID-19 patients.Methods A systematic review and meta-analysis was conducted by systematically searching electronic databases.Key findings The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94).Conclusions The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

引用

页码：259 / 264

页数：6

共 5 条

[1] Serum uric acid, disease severity and outcomes in COVID-19 [J].